{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:57Z","timestamp":1753891977254,"version":"3.41.2"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Sorafenib-related dermatological toxicity is a well-known adverse reaction that can severely affect therapeutic outcomes. Rash\/desquamation with its variable manifestations is one of the common clinical presentations. Currently, no standard continuum of care for sorafenib-related rash\/desquamation has been established.<\/jats:p><jats:p><jats:bold>Case summary:<\/jats:bold> A 75-year-old woman with colorectal cancer who developed unresectable hepatocellular carcinoma (uHCC) received, six years later, sorafenib 400\u00a0mg twice daily. She developed a Grade-3 Common Terminology Criteria for Adverse Events (CTCEA) rash and bullae bilaterally on her lower extremities after 2\u00a0weeks of sorafenib use. Rash and blisters began to appear on the left calf and then merged as large bullae full of liquid and spread to both lower extremities. The bullae then erupted and skin began to slough off, which affected the patient\u2019s normal daily functioning. To lessen the condition, sorafenib was stopped permanently and dexamethasone intravenous (IV) infusion at 5\u00a0mg daily for 3\u00a0days and piperacillin\/tazobactam were used. The skin dried without exudate or ulcerations after a month.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> For severe (CTCAE Grade 3 or above) sorafenib-related rash\/desquamation, short-term corticosteroid pulse therapy at large doses is usually effective with routine skin care, and antibiotics can be considered if infection is present. Permanent cessation of sorafenib should be considered if severe manifestations such as erythema multiforme (EM) and Steven-Johnson syndrome (SJS) are suspected.<\/jats:p>","DOI":"10.3389\/fphar.2022.994865","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T12:57:31Z","timestamp":1663073851000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Severe rash\/desquamation induced by sorafenib in an uHCC patient and its clinical management"],"prefix":"10.3389","volume":"13","author":[{"given":"Yan","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2340\/00015555-0517","article-title":"Severe cutaneous reaction to sorafenib: Induction of tolerance","volume":"88","author":"Bauer","year":"2008","journal-title":"Acta Derm. Venereol."},{"key":"B2","unstructured":"Package insert: Sorafenib 200 mg tablets2018"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.seminoncol.2014.01.001","article-title":"Management of sorafenib-related adverse events: A clinician\u2019s perspective","volume":"41","author":"Brose","year":"2014","journal-title":"Semin. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial.","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1200\/JCO.2008.16.3279","article-title":"Phase II trial of sorafenib in advanced thyroid cancer","volume":"26","author":"Gupta-Abramson","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1159\/000351918","article-title":"Stevens-johnson syndrome induced by sorafenib for metastatic renal cell carcinoma","volume":"91","author":"Ikeda","year":"2013","journal-title":"Urol. Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/jjco\/hys103","article-title":"Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma","volume":"42","author":"Ikeda","year":"2012","journal-title":"Jpn. J. Clin. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/annonc\/mdq299","article-title":"Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma","volume":"21","author":"Kodaira","year":"2010","journal-title":"Ann. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1742-1241.2012.02940.x","article-title":"First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study","volume":"66","author":"Lencioni","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"B11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B12","unstructured":"Hepatobiliary cancers (version 1.2022)2022"},{"key":"B13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jaad.2008.06.034","article-title":"Dermatologic symptoms associated with the multikinase inhibitor sorafenib","volume":"60","author":"Robert","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1056\/nejm199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/1752-1947-4-338","article-title":"Late presentation of sorafenib- associated rash: A case report","volume":"4","author":"Sarkodie","year":"2010","journal-title":"J. Med. Case Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in stevens\u2013johnson syndrome and toxic epidermal necrolysis: Comparison with case\u2013control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"304","DOI":"10.4168\/aair.2015.7.3.304","article-title":"Sorafenib induces delayed-onset cutaneous hypersensitivity: A case series","volume":"7","author":"Sohn","year":"2015","journal-title":"Allergy Asthma Immunol. Res."},{"key":"B18","unstructured":"Common Terminology Criteria for adverse events v5.0 (CTCAE)2017"},{"key":"B19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","article-title":"Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines","volume":"32","author":"Vogel","year":"2021","journal-title":"Ann. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1053\/j.seminoncol.2014.01.002","article-title":"Management of common adverse events in patients treated with sorafenib: Nurse and pharmacist perspective","volume":"41","author":"Walko","year":"2014","journal-title":"Semin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1365-2230.2011.04060.x","article-title":"Meta-analysis of dermatological toxicities associated with sorafenib","volume":"36","author":"Zhang","year":"2011","journal-title":"Clin. Exp. Dermatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.994865\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T12:57:37Z","timestamp":1663073857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.994865\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":21,"alternative-id":["10.3389\/fphar.2022.994865"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.994865","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2022,9,13]]},"article-number":"994865"}}